HRMY Quote, Financials, Valuation and Earnings

Incyte has a net margin of 24.78% compared to Harmony Biosciences Holdings's net margin of 9.36%. Harmony Biosciences Holdings's return on equity of 23.59% beat Incyte's return on equity of 0.75%.

Harmony Biosciences Holdings has a consensus price target of $53.88, signalling upside risk potential of 57.53%. On the other hand Incyte has an analysts' consensus of $79.38 which suggests that it could grow by 14.66%. Given that Harmony Biosciences Holdings has higher upside potential than Incyte, analysts believe Harmony Biosciences Holdings is more attractive than Incyte.

Harmony Biosciences Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Incyte has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.381%.

Harmony Biosciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Incyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings pays -- of its earnings as a dividend. Incyte pays out -- of its earnings as a dividend.

Harmony Biosciences Holdings quarterly revenues are $186M, which are smaller than Incyte quarterly revenues of $1.1B. Harmony Biosciences Holdings's net income of $46.1M is lower than Incyte's net income of $106.5M. Notably, Harmony Biosciences Holdings's price-to-earnings ratio is 16.21x while Incyte's PE ratio is 494.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings is 2.91x versus 3.68x for Incyte. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 24.78% compared to Harmony Biosciences Holdings's net margin of 36.03%. Harmony Biosciences Holdings's return on equity of 23.59% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Harmony Biosciences Holdings has a consensus price target of $53.88, signalling upside risk potential of 57.53%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 47.82%. Given that Harmony Biosciences Holdings has higher upside potential than Regeneron Pharmaceuticals, analysts believe Harmony Biosciences Holdings is more attractive than Regeneron Pharmaceuticals.

Harmony Biosciences Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Harmony Biosciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Harmony Biosciences Holdings quarterly revenues are $186M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Harmony Biosciences Holdings's net income of $46.1M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Harmony Biosciences Holdings's price-to-earnings ratio is 16.21x while Regeneron Pharmaceuticals's PE ratio is 17.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings is 2.91x versus 5.92x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Avidity Biosciences has a net margin of 24.78% compared to Harmony Biosciences Holdings's net margin of -3441.7%. Harmony Biosciences Holdings's return on equity of 23.59% beat Avidity Biosciences's return on equity of -30.66%.

Harmony Biosciences Holdings has a consensus price target of $53.88, signalling upside risk potential of 57.53%. On the other hand Avidity Biosciences has an analysts' consensus of $68.27 which suggests that it could grow by 126.74%. Given that Avidity Biosciences has higher upside potential than Harmony Biosciences Holdings, analysts believe Avidity Biosciences is more attractive than Harmony Biosciences Holdings.

Harmony Biosciences Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Avidity Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Harmony Biosciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avidity Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings pays -- of its earnings as a dividend. Avidity Biosciences pays out -- of its earnings as a dividend.

Harmony Biosciences Holdings quarterly revenues are $186M, which are larger than Avidity Biosciences quarterly revenues of $2.3M. Harmony Biosciences Holdings's net income of $46.1M is higher than Avidity Biosciences's net income of -$80.4M. Notably, Harmony Biosciences Holdings's price-to-earnings ratio is 16.21x while Avidity Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings is 2.91x versus 292.86x for Avidity Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 24.78% compared to Harmony Biosciences Holdings's net margin of 37.71%. Harmony Biosciences Holdings's return on equity of 23.59% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Harmony Biosciences Holdings has a consensus price target of $53.88, signalling upside risk potential of 57.53%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 20.76%. Given that Harmony Biosciences Holdings has higher upside potential than Vertex Pharmaceuticals, analysts believe Harmony Biosciences Holdings is more attractive than Vertex Pharmaceuticals.

Harmony Biosciences Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

Harmony Biosciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Harmony Biosciences Holdings quarterly revenues are $186M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Harmony Biosciences Holdings's net income of $46.1M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Harmony Biosciences Holdings's price-to-earnings ratio is 16.21x while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings is 2.91x versus 10.01x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.